CIENCIASMEDICASNEWS

domingo, 30 de agosto de 2026

Disrupted brain-immune signaling may help drive neurodegeneration +++

Exhausted T cells can escape tumors and confer long-lasting immunity to cancer in miceExhausted T cells can escape tumors and confer long-lasting immunity to cancer in mice https://www.news-medical.net/news/20260818/Exhausted-T-cells-can-escape-tumors-and-confer-long-lasting-immunity-to-cancer-in-mice.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026 As the immune system battles cancer, chronic stimulation gradually drives T cells to a state of exhaustion. The perception was that intratumoral T cells expressing LAG3 perform no function: they either just sit there or they die. So, it was both surprising and exciting to see that they can actually drive long-lasting immune memory, a finding that has potential translational implications for LAG3-targeting cancer immunotherapies." Dario A.A. Vignali, senior author, chair and distinguished professor of immunology, University of Pittsburgh School of Medicine Scientists create brain organoids with distinct cortical regional identityScientists create brain organoids with distinct cortical regional identity https://www.news-medical.net/news/20260820/Scientists-create-brain-organoids-with-distinct-cortical-regional-identity.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026 The human brain is often described as one of the most complex structures in biology, and much of its power comes from how it's organized. Aging shifts memories from vivid details to bigger pictureAging shifts memories from vivid details to bigger picture https://www.news-medical.net/news/20260821/Aging-shifts-memories-from-vivid-details-to-bigger-picture.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026 Research from the University of East Anglia shows how our memories change with age and why specific details associated with past events can fade over time.

Disrupted brain-immune signaling may help drive neurodegeneration ++

Disrupted brain-immune signaling may help drive neurodegeneration From gut-primed T cells to microglial signaling and persistent gene-regulatory states, researchers map an intricate immune network that connects the brain with the rest of the body. https://www.news-medical.net/news/20260824/Disrupted-brain-immune-signaling-may-help-drive-neurodegeneration.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026 Immune cells communicate across a continuous, bidirectional circuit between the CNS and periphery. Immune cells from across the body engage CNS tissues and, in turn, are shaped by signals returning from the brain. (Left) Under peripheral equilibrium, immune effectors mobilized from visceral organs, secondary lymphoid organs, hematopoietic tissues, and the peripheral nervous system (PNS) - including CD4+ and CD8+ T cells, B cells, monocytes (top 3 cell types), NK cells, dendritic cells, mast cells, neutrophils, and innate lymphoid cells (bottom cluster of cells) - engage the CNS in a homeostatic dialogue that supports neural cell health, plasticity, and repair, sustaining a protective environment. (Right) Age-associated dysfunction across the same peripheral compartments reshapes this circuit: altered immune effectors enter the CNS and contribute to shifting the local environment toward a degenerative state in which microglia adopt disease-associated programs, astrocytes become reactive, and neurons accumulate pathology. This model underscores how the same circuitry can yield protective or pathogenic outcomes and that neurodegeneration is downstream of dysfunctional brain-immune crosstalk. Study: Neurodegeneration as a dysregulation of neuroimmune crosstalk New brain wave theory explains cognition and consciousness A new theory, published in The Journal of Neuroscience by three scientists in The Picower Institute for Learning and Memory at MIT, offers an explanation of how the brain produces cognition and consciousness: It uses traveling waves of rhythmic neural activity to coordinate nimble neural networks with analog computations. https://www.news-medical.net/news/20260820/New-brain-wave-theory-explains-cognition-and-consciousness.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_25_august_2026

Rapid pathway for diagnosing heart attacks does not improve emergency discharge rates

https://www.news-medical.net/news/20260829/Rapid-pathway-for-diagnosing-heart-attacks-does-not-improve-emergency-discharge-rates.aspx A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither reduced the length of time patients spent in the ED nor increased direct discharge from the ED. These were the main findings of the PRESC1SE-MI trial and an independent participant data meta-analysis of all randomized trials presented in a Hot Line session today at ESC Congress 2026. The findings were published simultaneously in The Lancet.

Breast cancer survivors could avoid lifelong heart medication, research suggests

https://www.news-medical.net/news/20260830/Breast-cancer-survivors-could-avoid-lifelong-heart-medication-research-suggests.aspx Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich.

FDA approves first RAS-targeting drug for pancreatic cancer Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week. Brought to you byDDN editorial team

FDA approves first RAS-targeting drug for pancreatic cancer Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/fda-approves-first-ras-targeting-drug-for-pancreatic-cancer-17485 The FDA has approved Revolution Medicines’ Rasonque (daraxonrasib) for adults with advanced pancreatic adenocarcinoma, marking the first approved therapy designed to directly target a genetic driver of the disease. The once-daily oral RAS inhibitor is approved for patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are not candidates for multiagent treatment. In a randomized Phase 3 trial involving 500 previously treated patients, Rasonque more than doubled median overall survival compared with standard chemotherapy, extending it to 13.2 months versus 6.7 months. Although pancreatic cancer accounts for only around three percent of cancer diagnoses in the US, it is responsible for approximately eight percent of cancer deaths, with more than 50,000 people dying from the disease each year. Rasonque targets RAS proteins, which drive tumor growth in most pancreatic adenocarcinomas, and was granted Breakthrough Therapy, Orphan Drug, and Priority Review designations. “The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions,” said Angelo de Claro, Director of the FDA’s Oncology Center of Excellence, in the press release. – Bree Foster

Guideline Essentials Guideline Summaries +... ++++ ++++

Guideline Essentials Guideline Summaries https://reference.medscape.com/guidelines?ecd=mkm_ret_260830_mscpmrk-OUS_InFocus_etid8633402&uac=148436CN&impID=8633402 Multiple Myeloma and MGUS: DKG/DKH/AWMF 2022 Guideline Summary Diagnosis, Treatment, and Follow Up for MGUS and Multiple Myeloma Source: German Cancer Society, German Cancer Aid, Association of the Scientific Medical Societies in Germany · AWMF https://reference.medscape.com/cc2/p10/dkg-awmf-guideline-mgus-multiple-myeloma-2026a1000tli Multiple Myeloma, Adults: DGHO 2024 Guideline Summary Diagnosis, Staging, and Management of Multiple Myeloma Source: German Society for Hematology and Medical Oncology · DGHO https://reference.medscape.com/cc2/p10/dgho-guideline-multiple-myeloma-2026a1000tkm Myelofibrosis Diagnosis and Management: DGHO 2025 Guideline Summary Myelofibrosis: Diagnosis, Risk Stratification, and Treatment Source: German Society for Hematology and Medical Oncology · DGHO https://reference.medscape.com/cc2/p10/dgho-guideline-myelofibrosis-diagnosis-treatment-2026a1000tq7 Atopic Dermatitis, Topical Treatment: AAD 2023 Guideline Summary Topical Therapies for Atopic Dermatitis in Adults Source: American Academy of Dermatology; Medically Reviewed by Professor William James https://reference.medscape.com/cc2/p10/aad-topical-therapies-atopic-dermatitis-adults-guideline-2026a1000srk Immunizations for People with HIV: NIH/HIVMA/IDSA 2026 Guideline Summary Immunizations for Adults and Adolescents With HIV Source: National Institutes of Health, HIV Medicine Association, Infectious Diseases Society of America https://reference.medscape.com/cc2/p10/idsa-nih-immunizations-adults-and-adolescents-hiv-guideline-2026a1000t0i Pancreatitis: NICE 2026 Guideline Summary Pancreatitis Source: National Institute for Health and Care Excellence https://reference.medscape.com/cc2/p10/pancreatitis-guidelines-nice-2026a1000sy2 Diabetes, High Hypoglycemia Risk: ES 2022 Guideline Summary Management of Individuals With Diabetes at High Risk for Hypoglycemia Source: Endocrine Society · ES https://reference.medscape.com/cc2/p10/diabetes-high-risk-hypoglycemia-endocrine-guidelines-2026a1000rem Aggressive Pituitary Tumours: ESE 2025 Guideline Summary Aggressive Pituitary Tumours and Pituitary Carcinomas Source: European Society of Endocrinology https://reference.medscape.com/cc2/p10/ese-guideline-aggressive-pituitary-tumours-2026a1000qo3